TGFβ-activated Asporin interacts with STMN1 to promote prostate cancer docetaxel chemoresistance and metastasis by upregulating the Wnt/β-catenin signaling pathway.

Aims: Prostate cancer (PCa) remains a significant challenge in oncology due to high rates of drug resistance following standard treatment with docetaxel-based chemotherapy. Asporin (ASPN) has been regarded as an oncogene and its upregulation is closely associated with malignant behavior and poor prognosis in multiple cancers. Studies indicated that abnormal activation of the Wnt/β-catenin signaling pathway is prevalent in PCa.

Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients.

The human genome project ushered in a genomic medicine era that was largely unimaginable three decades ago. Discoveries of druggable cancer drivers enabled biomarker-driven gene- and immune-targeted therapy and transformed cancer treatment. Minimizing treatment not expected to benefit, and toxicity-including financial and time-are important goals of modern oncology.

Unveiling radiobiological traits and therapeutic responses of BRAF-mutant colorectal cancer via patient-derived organoids.

Background: Radiotherapy (RT) is an essential treatment for colorectal cancer (CRC), yet the factors influencing radiosensitivity remain unclear. In the quest to enhance the therapeutic efficacy in CRC, the interplay between genetic mutations and RT sensitivity has emerged as a pivotal yet enigmatic area.

Methods: We harness the fidelity of patient-derived organoids (PDOs) to dissect the molecular landscape of radiosensitivity, with a particular emphasis on BRAF mutations.

Antibody-DNA nanostructure conjugate enables targeted delivery of gemcitabine to tumor and improves the anti-tumor efficacy.

Antibody drug conjugate has emerged as one of the most successful drug delivery systems in recent years. Leveraging the inherent self-assembly and efficient intracellular internalization capabilities of DNA nanostructures, this study aimed to develop antibody-DNA nanostructure conjugates based on gemcitabine, which drug antibody ratio can reach 17.8.

p53 activates circASCC3 to repress R-loops and enhance resistance to chemotherapy.

The tumor suppressor p53 can trigger tumor resistance to chemotherapy by facilitating DNA damage repair and maintaining genomic integrity. Here, we report that a p53-induced circular RNA circASCC3 promotes chemotherapeutic resistance by resolving R-loops. Our results reveal that p53 directly activates the transcription of , the host gene of circASCC3.

Promotes the Growth and Metastasis of Colorectal Cancer by Activating E-Cadherin/Krüppel-Like Factor 4/Integrin α5 Signaling in a Calcium-Dependent Manner.

Gut microbiota and integrins are known to contribute to colorectal cancer (CRC), but whether they interact has been unclear. Here, we provided evidence that upregulated integrin α5 (ITGA5) in CRC in both human patients and murine models. Knocking down in CRC cells weakened the ability of to stimulate their malignant characteristics.

knockdown enhances RSL3-induced ferroptosis in pancreatic cancer cells and increases the sensitivity to gemcitabine.

Ferroptosis is a type of programmed death characterized by iron-dependent lipid peroxidation, and targeting ferroptosis has been shown to efficiently kill highly aggressive cancer cells. Previously, we confirmed that nuclear receptors regulate ferroptosis in pancreatic cancer. However, whether nuclear receptor co-activators regulate ferroptosis is unclear.

Robust Automatic Grading of Blunt Liver Trauma in Contrast-Enhanced Ultrasound Using Label-Noise-Resistant Models.

Recently, contrast-enhanced ultrasound (CEUS) has presented a potential value in the diagnosis of liver trauma, the leading cause of death in blunt abdominal trauma. However, the inherent speckle noise and the complicated visual characteristics of blunt liver trauma in CEUS images make the diagnosis highly dependent on the expertise of radiologists, which is subjective and time-consuming. Moreover, the intra- and inter-observer variance inevitably influences the accuracy of diagnosis using CEUS.

MAP17 contributes to the tumorigenesis of papillary thyroid carcinoma by activating the AKT signaling pathway.

Objective: This study investigates the role of membrane-associated protein 17 (MAP17) and the Akt signaling pathway in the progression of papillary thyroid carcinoma (PTC).

Materials And Methods: We conducted a series of in vitro experiments using PTC cell lines (HTori-3 and TPC-1). Cells were divided into three groups: control, MAP17 inhibitor negative control (NC), and MAP17 inhibitor treatment.

Limitations and enhancement opportunities for variceal rebleeding prediction model in patients with cirrhosis.

A multicenter study recently published introduced a novel prognostic model for predicting esophagogastric variceal rebleeding after endoscopic treatment in patients with cirrhosis. The model incorporated six readily available clinical variables-albumin level, aspartate aminotransferase level, white blood cell count, ascites, portal vein thrombosis, and bleeding signs-and demonstrated promising predictive performance. However, limitations, including the retrospective design and exclusion of patients with hepatocellular carcinoma, may affect the generalizability of the model.

[Challenges and strategies in minimally invasive pancreatic enucleation].

Minimally invasive enucleation of pancreatic tumors has become a focal topic in the field of pancreatic surgery. This technique, which allows for complete tumor removal while preserving maximal pancreatic function, has seen widespread application in clinical practice in recent years. Preoperative evaluation is essential, requiring a thorough assessment of the necessity, feasibility, and appropriateness of surgery, and a careful choice between follow-up observation, parenchyma-sparing resection, or radical resection.

Accelerometer-Derived "Weekend Warrior" Physical Activity and All-Cause and Cause-Specific Mortality.

Objective: To examine the association of "weekend warrior" (WW) pattern and physical activity distributed throughout the week with mortality risk.

Participants And Methods: In this cohort study of 95,468 participants in the UK Biobank from 2013 through 2015, participants were grouped by accelerometer-derived physical activity levels: inactive (moderate to vigorous physical activity [MVPA] <150 min/wk using World Health Organization guidelines), active WW (≥150 minutes of MVPA per week and ≥50% of total MVPA over 1 to 2 days), and active regular (≥150 minutes of MVPA but not active WW). Cox regression analyzed associations of activity patterns with all-cause mortality and 10 categories of cause-specific mortality and whether the association differed by sedentary time (≤6, 7 to 12, or ≥13 hours) and light physical activity (≤60, 61 to 150, or ≥151 min/d).

Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study.

Preclinical studies suggest synergistic effects between androgen receptor inhibitors and poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors. This phase 2 trial (NCT05223582) evaluates neoadjuvant fuzuloparib plus abiraterone in 35 treatment-naive men with localized high-risk prostate cancer. Patients receive six cycles of therapy followed by radical prostatectomy.

LTA4H improves the tumor microenvironment and prevents HCC progression via targeting the HNRNPA1/LTBP1/TGF-β axis.

Leukotriene A4 hydrolase (LTA4H), an inflammatory mediator, has garnered attention for its role in the development of chronic lung diseases and various cancers. Our study highlights the protective role of LTA4H in hepatocellular carcinoma (HCC) occurrence and progression. LTA4H is downregulated in clinical and mouse HCC tumors.

The pancreatitis-cancer transformation-related factor, human rhomboid family-1, promotes pancreatic cancer progression through the SRC/YAP signaling pathway.

Pancreatic cancer is an aggressive malignancy characterized by rapid progression, unfavorable outcomes, and a low early detection rate. Elucidating the mechanisms underlying the onset and progression of pancreatic tumors is essential for early detection and for developing preventive measures. Even though human rhomboid family-1 (RHBDF) acts as an oncogene in various tumors, the role of RHBDF in pancreatic cancer progression remains unexplored.

A questionnaire-based cross-sectional survey of cutaneous adverse events in cancer patients treated with molecular targeted therapy and immunotherapies.

Background: Advances in anticancer treatments have significantly improved disease control and progression-free survival. These therapies are associated with various adverse events (AEs), especially cutaneous toxicities. However, there is a paucity of patient-reported outcomes on cutaneous AEs (CAEs) and associated alternation of quality of life (QoL) in cancer patients.

Overcoming Matrix Barriers for Enhanced Immune Infiltration Using siRNA-Coated Metal-Organic Frameworks.

The extracellular matrix (ECM) of solid tumor constitutes a formidable physical barrier that impedes immune cell infiltration, contributing to immunotherapy resistance. Breast cancer, particularly triple-negative breast cancer (TNBC), is characterized by a collagen-rich tumor microenvironment, which is associated with T cell exclusion and poor therapeutic outcomes. Discoidin domain receptor 2 (DDR2) and integrins, key ECM regulatory receptors on cancer cells, play pivotal role in maintaining this barrier.

Hypoxia inducible factor-1α drives cancer resistance to cuproptosis.

Cuproptosis represents a new type of cell death that intricately associated with copper homeostasis and protein lipoylation. The cuproptosis suppression has been characterized in the hypoxic tumor microenvironment (TME). Here we reveal that hypoxia inducible factor-1α (HIF-1α) is a driver of cuproptosis resistance in solid tumor.

Radiation Dose-Volume Effects on Negative Tumor-Draining Lymph Nodes Impacted T-Cell Activation and Prognosis in Esophageal Cancer with Chemoradiotherapy.

Purpose: Preclinical model found that elective nodal irradiation (ENI) attenuated the efficacy of radiotherapy and radio-immunotherapy. However, limited clinical studies have explored the correlation between radiation dose-volume parameters of negative tumor draining lymph nodes (TDLNs) and T-cell activation/prognosis for cancer patients treated with definitive radio(chemo)therapy.

Experimental Design: Patients with locally advanced esophageal cancer undergoing definitive chemoradiotherapy (CRT) were selected from two prospective trials.

ISM1 regulates white adipose tissue remodelling by dampening adipocyte differentiation and enhancing inflammation.

Aims: Isthmin-1 (ISM1), a secretory protein predominantly derived from brown adipose tissue, enhances glucose tolerance and attenuates hepatic steatosis. However, its potential involvement in white adipose tissue remodelling remains elusive, which profoundly impacts adipocyte insulin sensitivity and consequently alters systemic metabolic homeostasis.

Materials And Methods: ISM1 expression profiles in human and mouse were systematically characterized using Tabula Sapiens.

Complete response to Mirvetuximab Soravtansine in platinum-resistant recurrent ovarian cancer: a case report.

Ovarian cancer, colloquially termed the "king of gynecological cancers," presents significant diagnostic and therapeutic challenges due to its covert nature. It ranks as the deadliest gynecologic malignancy with a disheartening 5-year survival rate below 40%. Standard therapeutic protocols for newly diagnosed patients encompass cytoreductive surgery followed by neoadjuvant or adjuvant platinum-based chemotherapy.

Noninvasive molecular imaging using anti-Trop-2 aptamer for targeted therapy of small cell lung cancer.

Recent advancements in antibody-drug conjugates (ADCs) targeting trophoblast surface cell antigen 2 (Trop-2) have brought important progress in the field of targeted therapy. This progress also holds promise for the treatment of small cell lung cancer (SCLC) as anti-Trop-2 therapy appears to have a safe and effective clinical activity in metastatic SCLC patients. However, effective treatments of anti-Trop-2 ADCs rely on the comprehensive assessment of Trop-2 expression at the tumor sites, SCLC exhibits intratumoral heterogeneity, making the accurate acquisition of histological biopsies a challenge.

Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase 2 trial.

Background: Standard neoadjuvant regimens for HER2-positive breast cancer include trastuzumab and pertuzumab combined with chemotherapy, and the efficacy and safety of third-generation HER2-direted antibody-drug conjugate (ADC) remain to be elucidated.

Patients And Methods: This open-label, randomized, phase 2 study enrolled patients aged 18 years or older with stage II-III Her2-positive breast cancer. Patients were randomly assigned (1:1:1) to receive neoadjuvant treatment either with SHR-A1811 monotherapy, SHR-A1811 with pyrotinib, or nab-paclitaxel combined with carboplatin, trastuzumab, and pertuzumab (PCbHP) for 24 weeks.